Human epidermal growth factor receptor 2-derived peptides presented on major histocompatibility complex class II (HER2-MHC II)

Human epidermal growth factor receptor 2 (HER2)-derived peptides presented on major histocompatibility complex (MHC) class II molecules serve as vital targets for cancer immunotherapy [1]. HER2 is a member of the epidermal growth factor receptor family that is frequently overexpressed in various cancers, leading to aggressive tumor growth [2]. When HER2 proteins are degraded, specific peptide fragments are loaded onto MHC class II molecules and displayed on the surface of antigen-presenting cells or tumor cells [3]. These complexes are specifically recognized by CD4+ T helper cells, which play a central role in orchestrating the anti-tumor immune response by secreting cytokines like interferon-gamma and providing help to CD8+ cytotoxic T cells [4]. Therapeutic interventions, such as the AE37 peptide vaccine, are designed to enhance the presentation of these HER2 epitopes to stimulate a robust and durable immune attack against HER2-positive malignancies [5]. Targeting the HER2-MHC II complex is particularly valuable for overcoming the limitations of MHC class I-restricted therapies, which often suffer from tumor-mediated MHC I downregulation [6]. Consequently, this target is a focal point for developing next-generation vaccines and cell-based therapies aimed at treating breast, gastric, and ovarian cancers [7].

Other names

HER2-HLA class II complexHER2/neu MHC-II restricted epitopespMHC-II (HER2)HER2-derived CD4+ T-cell epitopesERBB2-derived peptides presented on MHC class II

Activation of CD4+ T helper cells through the recognition of HER2-derived epitopes presented on MHC class II, leading to the secretion of pro-inflammatory cytokines (e.g., IFN-gamma) and the enhancement of CD8+ cytotoxic T cell and B cell responses [4, 5].